伤口护理市场研究

---

我们可以在家中通过急救治疗治愈小伤口和损伤。有些伤口较大或较深。此外，此类伤口需要医疗专业人员帮助愈合并防止感染。伤口护理中心是另一种治疗未愈合伤口的医疗机构。您是否受伤两周了，却没有愈合的迹象？那么，如果您去伤口护理机构会有所帮助。六周的伤口尚未完全愈合，则属于慢性伤口。这样的伤口需要伤口护理机构的进一步护理。

为什么伤口护理很重要？

当人们不照顾伤口或疮口时，这可能会成为一个严重的健康问题。伤口分为急性伤口和慢性伤口。慢性伤口在四到六周后没有愈合的迹象。当伤口不愈合时，它们会导致感染、疼痛、残疾甚至截肢。我们不能轻视伤口护理的重要性。只要慢性伤口得不到治疗，就有可能被感染。

Wound Care Market Research: How Leading Manufacturers Win Clinician Preference

Wound care is a clinician-led category. The nurse at the bedside, not the procurement contract, decides which dressing comes off the cart. Manufacturers who understand this win share. Those who optimize for hospital formulary alone leave growth on the table.

The category rewards specificity. Antimicrobial dressings, negative pressure wound therapy, collagen matrices, and skin substitutes each follow different adoption logics. Wound care market research that treats them as one segment produces generic insight. Research that isolates the decision maker, the wound type, and the care setting produces commercial advantage.

Why Wound Care Market Research Rewards Clinician-Level Depth

The prescriber in wound care is rarely the physician of record. Wound ostomy continence nurses (WOCNs), wound care directors, and nurse practitioners drive product selection in long-term care, home health, and hospital outpatient departments. They build treatment outlines based on exudate level, bioburden, periwound condition, and healing trajectory. They escalate to silver, iodine, or PHMB antimicrobials when stalled wounds show biofilm signatures.

SIS International’s structured expert interviews with wound care nurses and WOCNs across U.S. acute and post-acute settings indicate that antimicrobial dressing selection is governed less by brand preference than by a two-week trial-and-escalate protocol tied to wound bed appearance. Manufacturers who map their value story to that escalation logic enter the consideration set. Those who lead with mechanism-of-action claims disconnected from the clinician’s decision sequence get filtered out before sampling.

This is why surveys alone underperform in wound care. The decision is tactile and visual. Clinicians evaluate conformability, exudate handling, atraumatic removal, and wear time at the dressing change. Concept tests without product-in-hand evaluation miss the variables that actually drive switching.

The Four Decision Axes That Shape Wound Care Adoption

Effective wound care market research isolates four axes that determine commercial uptake. Each carries different evidence requirements and different KOL mapping needs.

Source: SIS International Research

Manufacturers often build a single launch narrative across all four. The narrative collapses on contact with the value analysis committee, which speaks the language of cost per healed wound, not clinical novelty. It also collapses with the home health agency, which optimizes for nurse visits per episode under PDGM reimbursement.

What Patient Journey Mapping Reveals in Chronic Wound Categories

Diabetic foot ulcers, venous leg ulcers, and pressure injuries each follow distinct referral and reimbursement pathways. A diabetic foot ulcer patient may pass through primary care, podiatry, vascular surgery, and a wound center within a single episode. Each handoff is a product decision point. Each clinician operates under different incentives.

Patient journey mapping in wound care identifies where products enter, exit, and get switched. It also surfaces the abandonment points. Across SIS International’s qualitative work with U.S. wound care clinicians, a recurring pattern emerges: products selected in the wound center are frequently substituted within seven to fourteen days of home health transition because the home agency stocks a different formulary. Manufacturers who fail to model the cross-setting handoff lose volume they assumed they had won.

This is where real-world evidence and claims-linked analysis complement primary qualitative work. The clinician interview reveals the why. The claims data reveals the where and how often. Together they shape a payer value story that addresses cost per healed wound across the full episode rather than the single dressing change.

How Leading Manufacturers Build Launch Sequencing for Advanced Modalities

Skin substitutes, cellular and tissue-based products, and negative pressure wound therapy operate under reimbursement structures that change adoption math entirely. CMS coverage decisions, the LCD for cellular and tissue products, and the transition of skin substitutes to ASP-based reimbursement reshape which products get used and where. Indication prioritization matters here. A product cleared for diabetic foot ulcers and venous leg ulcers may see ninety percent of its volume in one indication based on reimbursement and KOL endorsement, not clinical breadth.

Launch sequencing should follow the reimbursement gradient. Hospital outpatient departments and wound centers with established billing infrastructure absorb advanced modalities first. Physician offices follow. Home health is last because payment models lag. Manufacturers who launch broadly and uniformly burn commercial spend on accounts that cannot yet bill the product profitably.

The SIS Approach to Wound Care Market Research

SIS International conducts wound care market research through B2B expert interviews with WOCNs, wound care directors, vascular surgeons, podiatrists, and home health clinical leaders, paired with concept and product evaluation sessions that put the dressing in the clinician’s hands. This combination surfaces the prescription behavior, the escalation triggers, and the tactile evaluation that drive switching. It also tests the payer value story against the value analysis committee logic before launch.

SIS International’s proprietary research in antimicrobial wound care indicates that clinicians evaluate new dressings against a mental benchmark of their current go-to product, and that benchmark shifts only when the new product demonstrates a clear advantage on either wear time, exudate handling, or atraumatic removal. Generic superiority claims do not move the benchmark. Specific, clinician-relevant proof points do.

The firms that grow share in wound care invest in clinician-level intelligence before committing to launch sequencing, KOL mapping, and formulary positioning. Wound care market research conducted at that depth turns a crowded category into a defensible position.

关于 SIS 国际

SIS 国际 提供定量、定性和战略研究。我们提供决策所需的数据、工具、战略、报告和见解。我们还进行访谈、调查、焦点小组和其他市场研究方法和途径。 联系我们 为您的下一个市场研究项目提供帮助。